Synthesis and antibacterial activity of novel 7-(3-substituted-3 or 4- trifluoromethyl-1-pyrrolidinyl)-8-methoxyfluoroquinolones

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 20, 1998, Pages 2833-2838

  Fukui, Hideto ^a   Shibata, Tetsuo ^a   Naito, Takanobu ^a   Nakano, Jun ^a   Maejima, Tetsuro ^a   Senda, Hisato ^a   Iwatani, Wakao ^a   Tatsumi, Yoshiyuki ^a   Suda, Masahiro ^a   Arika, Tadashi ^a  

^a KAKEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Antibacterials; Bacteria; Chemotherapy

Indexed keywords

7 (3 AMINOMETHYL 4 TRIFLUOROMETHYL 1 PYRROLIDINYL) 1 CYCLOPROPYL 6 FLUORO 1,4 DIHYDRO 8 METHOXY 4 OXOQUINOLINE 3 CARBOXYLIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; S 34109; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CHIRALITY; CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; METHYLATION; NONHUMAN; PENICILLIN RESISTANCE; ULTRAVIOLET RADIATION; X RAY CRYSTALLOGRAPHY;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MULTIPLE; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PYRROLIDINES; STAPHYLOCOCCUS AUREUS;

EID: 0032552934     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00514-9     Document Type: Article

References (17)

1. [1] For a review, see: Mitsuhashi S, Ed. Fluorinated Quinolones - New Quinolone Antimicrobials. In Progress in Drug Research; Birkhäuser Verlag: Basel, 1992;38:10-147.
2. [2] Forstall GJ, Knapp CC, Washington JA. Antimicrob. Agents Chemother. 1991;35:1679-1681.
3. [3] Suto MJ, Domagala JM, Roland GE, Mailloux GB, Cohen MA. J. Med. Chem, 1992;35:4745-4750.
4. [4] Domagala JM J. Antimicrob. Chemother. 1994;33:685-706.
5. [5] Matsumoto M, Kojima K, Nagano H, Matsubara S, Yokota T. Antimicrob. Agents Chemother. 1992;36:1715-1719.
6. [6] Bégué J-P, Bonnet-Delpon D, Lequeux T. Tetrahedron Lett. 1993;34:3279-3282.
7. [7] The synthesis of 5b and 5c in a way similar to ours has been recently reported: Li Q, Wang W, Berst KB, Claibome A, Hasvold L, Raye K, Tufano M, Nilius A, Shen LL, Flamm R, Alder J, Marsh K, Crowell DA, Chu DTW, Plattner JJ. Bioorg. Med. Chem. Lett. 1998;8:1953-1958.
8. [8] Huang Y, Shen Y, Xin Y, Wang Q, Wu W. Acta Sci. Sin. Ser. B 1982;25:21-28.
9. [9] Iwata M, Kimura F, Fujiwara Y. Jpn. Kokai Tokkyo Koho JP 3-7261.
10. 35 = -17,5°(c 1.00, MeOH).
11. [11] Fukui H, Kobayashi K, Nakata T, Shibata T, Naito T, Nakano J. Anal. Sci. 1997;13:689-691.
12. [12] MICs were determined in accordance with the method of the MIC Committee of the Japan Society of Chemotherapy; Chemotherapy 1981;29:76-79.
13. 50.
14. [14] Tada H, Shiho O, Kuroshima K, Koyama M, Tsukamoto K. J. Immunol. Method. 1986; 93:157.
15. [15] Micronucleus test: Male Crj:CD-1 mice(8weeks old) were intraperitoneally given test drugs (suspension in olive oil) twice. The peripheral blood was collected from a tail blood vessel at 24-h intervals from 0 to 72 h after the first administration. Blood smear preparations were made by staining with acridine orange. Micronucleated reticulocytes (MNRETs) were observed with fluorescent microscopy. The group which showed the higher MNRET frequency than that before the administration was considered as positive.
16. [16] Maejima T, Senda H, Iwatani W, Tatsumi Y, Arika T, Fukui H, Shibata T, Nakano J, Naito T. 35th ICAAC 1995;Abstract No.F189.
17. 6) δ (ppm): 1.04-1.15 (m, 4H), 2.77-2.82 (m, 1H), 2.94-3.12 (m, 2H), 3.37-3.40 (m, 1H), 3.50-3.56 (m, 1H), 3.64 (s, 3H), 3.68 (dd, J = 11.1, 4.5Hz, 1H), 3.86-3.95 (m, 2H), 4.16-4.17 (m, 1H), 7.75 (d, J = 13.2 Hz, 1H), 8.33 (s, 3H), 8.70 (s, 1H), 14.94 (s, 1H).